Search terms: ISYSLANG IT |
IN THE HOUSE OF REPRESENTATIVES
BY HEALTH AND WELFARE COMMITTEE
1
AN ACT
2
3
4
THAT CERTAIN NABIXIMOLS SHALL NOT BE CONSIDERED SCHEDULE I CONTROLLED
5
SUBSTANCES AND TO MAKE TECHNICAL CORRECTIONS; AND DECLARING AN EMER-
6
GENCY AND PROVIDING AN EFFECTIVE DATE.
8
9
amended to read as follows:
10
37-2701. DEFINITIONS. As used in this chapter:
11
(a) "Administer" means the direct application of a controlled sub-
12
stance whether by injection, inhalation, ingestion, or any other means to
13
the body of a patient or research subject by:
14
(1) A practitioner or, in his presence, by his authorized agent; or
15
(2) The patient or research subject at the direction and in the presence
16
of the practitioner.
17
(b) "Agent" means an authorized person who acts on behalf of or at the
18
direction of a manufacturer, distributor or dispenser. It does not include
19
a common or contract carrier, public warehouseman or employee of the carrier
20
or warehouseman.
21
(c) "Board" means the state board of pharmacy created in chapter 17, ti-
22
23
24
department of justice, or its successor agency.
25
(e) "Controlled substance" means a drug, substance or immediate pre-
26
cursor in schedules I through VI of article II of this chapter.
27
(f) "Counterfeit substance" means a controlled substance which, or the
28
container or labeling of which, without authorization, bears the trademark,
29
trade name, or other identifying mark, imprint, number or device, or any
30
likeness thereof, of a manufacturer, distributor or dispenser other than the
31
person who in fact manufactured, distributed or dispensed the substance.
32
(g) "Deliver" or "delivery" means the actual, constructive, or at-
33
tempted transfer from one person to another of a controlled substance,
34
whether or not there is an agency relationship.
35
36
(i) "Dispense" means to deliver a controlled substance to an ultimate
37
user or research subject by or pursuant to the lawful order of a practi-
38
tioner, including the packaging, labeling, or compounding necessary to
39
prepare the substance for that delivery.
40
(j) "Dispenser" means a practitioner who dispenses.
41
(k) "Distribute" means to deliver other than by administering or dis-
42
pensing a controlled substance.
2
1
(l) "Distributor" means a person who distributes.
2
3
sional licenses.
4
(n) "Drug" means: (1) substances recognized as drugs in the official
5
6
7
them; (2) substances intended for use in the diagnosis, cure, mitigation,
8
treatment or prevention of disease in man or animals; (3) substances, other
9
than food, intended to affect the structure or any function of the body of man
10
or animals; and (4) substances intended for use as a component of any article
11
specified in clause (1), (2), or (3) of this subsection. It does not include
12
devices or their components, parts, or accessories.
13
(o) "Drug paraphernalia" means all equipment, products and materials
14
of any kind used, intended for use, or designed for use in planting, propa-
15
gating, cultivating, growing, harvesting, manufacturing, compounding, con-
16
verting, producing, processing, preparing, testing, analyzing, packaging,
17
repackaging, storing, containing, concealing, injecting, ingesting, inhal-
18
ing, or otherwise introducing into the human body a controlled substance in
19
violation of this chapter. It includes, but is not limited to:
20
(1) Kits used, intended for use, or designed for use in planting, prop-
21
agating, cultivating, growing or harvesting of any species of plant
22
which is a controlled substance or from which a controlled substance can
23
be derived;
24
(2) Kits used, intended for use, or designed for use in manufacturing,
25
compounding, converting, producing, processing or preparing con-
26
trolled substances;
27
(3) Isomerization devices used, intended for use, or designed for use
28
in increasing the potency of any species of plant which is a controlled
29
substance;
30
(4) Testing equipment used, intended for use, or designed for use in
31
identifying or in analyzing the strength, effectiveness or purity of
32
controlled substances;
33
(5) Scales and balances used, intended for use, or designed for use in
34
weighing or measuring controlled substances;
35
(6) Diluents and adulterants, such as quinine hydrochloride, mannitol,
36
mannite, dextrose and lactose, used, intended for use, or designed for
37
use in cutting controlled substances;
38
(7) Separation gins and sifters used, intended for use, or designed for
39
use in removing twigs and seeds from, or in otherwise cleaning or refin-
40
ing, marijuana;
41
(8) Blenders, bowls, containers, spoons and mixing devices used,
42
intended for use, or designed for use in compounding controlled sub-
43
stances;
44
(9) Capsules, balloons, envelopes and other containers used, intended
45
for use, or designed for use in packaging small quantities of controlled
46
substances;
47
(10) Containers and other objects used, intended for use, or designed
48
for use in storing or concealing controlled substances;
3
1
(11) Hypodermic syringes, needles and other objects used, intended
2
for use, or designed for use in parenterally injecting controlled sub-
3
stances into the human body;
4
(12) Objects used, intended for use, or designed for use in ingesting,
5
inhaling, or otherwise introducing marijuana, cocaine, hashish, or
6
hashish oil into the human body, such as:
7
(i) Metal, wooden, acrylic, glass, stone, plastic, or ceramic
8
pipes with or without screens, permanent screens, hashish heads,
9
or punctured metal bowls;
10
(ii) Water pipes;
11
(iii) Carburetion tubes and devices;
12
(iv) Smoking and carburetion masks;
13
(v) Roach clips: meaning objects used to hold burning material,
14
such as a marijuana cigarette, that has become too small or too
15
short to be held in the hand;
16
(vi) Miniature cocaine spoons and cocaine vials;
17
(vii) Chamber pipes;
18
(viii) Carburetor pipes;
19
(ix) Electric pipes;
20
(x) Air-driven pipes;
21
(xi) Chillums;
22
(xii) Bongs;
23
(xiii) Ice pipes or chillers;
24
In determining whether an object is drug paraphernalia, a court or other au-
25
thority should consider, in addition to all other logically relevant fac-
26
tors, the following:
27
1. Statements by an owner or by anyone in control of the object concern-
28
ing its use;
29
2. Prior convictions, if any, of an owner, or of anyone in control of the
30
object, under any state or federal law relating to any controlled sub-
31
stance;
32
3. The proximity of the object, in time and space, to a direct violation
33
of this chapter;
34
4. The proximity of the object to controlled substances;
35
5. The existence of any residue of controlled substances on the object;
36
6. Direct or circumstantial evidence of the intent of an owner, or of
37
anyone in control of the object, to deliver it to persons whom he knows,
38
or should reasonably know, intend to use the object to facilitate a vi-
39
olation of this chapter; the innocence of an owner, or of anyone in con-
40
trol of the object, as to a direct violation of this chapter shall not
41
prevent a finding that the object is intended for use or designed for use
42
as drug paraphernalia;
43
7. Instructions, oral or written, provided with the object concerning
44
its use;
45
8. Descriptive materials accompanying the object that explain or de-
46
pict its use;
47
9. National and local advertising concerning its use;
48
10. The manner in which the object is displayed for sale;
4
1
11. Whether the owner, or anyone in control of the object, is a legit-
2
imate supplier of like or related items to the community, such as a li-
3
censed distributor or dealer of tobacco products;
4
12. Direct or circumstantial evidence of the ratio of sales of the ob-
5
ject(s) to the total sales of the business enterprise;
6
13. The existence and scope of legitimate uses for the object in the com-
7
munity;
8
14. Expert testimony concerning its use.
9
(p) "Financial institution" means any bank, trust company, savings and
10
loan association, savings bank, mutual savings bank, credit union, or loan
11
company under the jurisdiction of the state or under the jurisdiction of an
12
13
(q) "Immediate precursor" means a substance which the board has found
14
to be and by rule designates as being the principal compound commonly used or
15
produced primarily for use, and which is an immediate chemical intermediary
16
used or likely to be used in the manufacture of a controlled substance, the
17
control of which is necessary to prevent, curtail or limit manufacture.
18
(r) "Isomer" means the optical isomer, except as used in section
19
20
(s) "Law enforcement agency" means a governmental unit of one (1) or
21
more persons employed full-time or part-time by the state or a political sub-
22
division of the state for the purpose of preventing and detecting crime and
23
enforcing state laws or local ordinances, employees of which unit are autho-
24
rized to make arrests for crimes while acting within the scope of their au-
25
thority.
26
(t) "Manufacture" means the production, preparation, propagation,
27
compounding, conversion or processing of a controlled substance, and in-
28
cludes extraction, directly or indirectly, from substances of natural
29
origin, or independently by means of chemical synthesis, or by a combina-
30
tion of extraction and chemical synthesis, and includes any packaging or
31
repackaging of the substance or labeling or relabeling of its container,
32
except that this term does not include the preparation or compounding of a
33
controlled substance:
34
(1) By a practitioner as an incident to his administering, dispensing
35
or, as authorized by board rule, distributing of a controlled substance
36
in the course of his professional practice; or
37
(2) By a practitioner, or by his authorized agent under his supervi-
38
sion, for the purpose of, or as an incident to, research, teaching, or
39
chemical analysis and not for delivery.
40
(u) "Marijuana" or "marihuana" means all parts of the plant of the
41
genus Cannabis, regardless of species, and whether growing or not; the seeds
42
thereof; the resin extracted from any part of such plant; and every compound,
43
manufacture, salt, derivative, mixture, or preparation of such plant, its
44
seeds or resin. It does not include:
45
(1) Industrial hemp or hemp possessed, grown, transported, farmed,
46
produced, processed, or possessed by any other entity engaged in haul-
47
ing, transporting, delivering, or otherwise moving hemp in interstate
48
or intrastate commerce pursuant to a license granted under the provi-
49
sions of the 2014 farm bill, the 2018 farm bill, 7 CFR 990.1 et seq.,
50
5
1
or "hemp" means the plant species Cannabis sativa L. and any part of
2
that plant, including the seeds thereof and all derivatives, extracts,
3
cannabinoids, isomers, acids, salts, and salts of isomers, whether
4
growing or not, with a measured total delta-9 tetrahydrocannabinol con-
5
centration of not more than three-tenths of one percent (0.3%) on a dry
6
weight or volume basis that shall determine the total delta-9 tetrahy-
7
drocannabinol (THC) concentration, including both delta-9 tetrahydro-
8
cannabinol and delta-9 tetrahydrocannabinolic acid (THCA) evaluated
9
by decarboxylation during analysis, or by measuring each compound and
10
calculating the total percentage of delta-9 tetrahydrocannabinol if
11
the THCA was decarboxylated, which must not exceed three-tenths of one
12
percent (0.3%).
13
(2) The mature stalks of the plant genus Cannabis unless the same are
14
intermixed with prohibited parts thereof, fiber produced from the
15
stalks, oil or cake made from the seeds or the achene of such plant, any
16
other compound, manufacture, salt, derivative, mixture, or preparation
17
of the mature stalks, except the resin extracted therefrom or where the
18
same are intermixed with prohibited parts of such plant, fiber, oil, or
19
cake, or the sterilized seed of such plant which is incapable of germi-
20
nation.
21
Evidence that any plant material or the resin or any derivative
22
thereof, regardless of form, that does not meet the definition of "indus-
23
trial hemp" or "hemp" as provided in this section, or that is possessed
24
without a license granted under the provisions of the 2014 farm bill,
25
the 2018 farm bill, 7 CFR 990.1 et seq., or the approved state plan for
26
27
as tetrahydrocannabinols shall create a presumption that such mate-
28
rial is "marijuana" as defined and prohibited herein. "Marijuana"
29
does not include drug product in finished dosage formulation that has
30
31
contains: (i) cannabidiol (2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclo-
32
hexen-1-yl]-5-pentyl-1,3-benzenediol), derived from cannabis and no more
33
than one-tenth of one percent (0.1%) (w/w) residual tetrahydrocannabinols;
34
or (ii) nabiximols.
35
(v) "Narcotic drug" means any of the following, whether produced di-
36
rectly or indirectly by extraction from substances of vegetable origin, or
37
independently by means of chemical synthesis, or by a combination of extrac-
38
tion and chemical synthesis:
39
(1) Opium and opiate, and any salt, compound, derivative, or prepara-
40
tion of opium or opiate.
41
(2) Any salt, compound, isomer, derivative, or preparation thereof
42
that is chemically equivalent or identical with any of the substances
43
referred to in clause (1), but not including the isoquinoline alkaloids
44
of opium.
45
(3) Opium poppy and poppy straw.
46
(4) Coca leaves and any salt, compound, derivative, or preparation of
47
coca leaves, and any salt, compound, isomer, derivative, or preparation
48
thereof which is chemically equivalent or identical with any of these
49
substances, but not including decocainized coca leaves or extractions
50
of coca leaves which do not contain cocaine or ecgonine.
6
1
(w) "Opiate" means any substance having an addiction-forming or ad-
2
diction-sustaining liability similar to morphine or being capable of
3
conversion into a drug having addiction-forming or addiction-sustaining
4
liability. It does not include, unless specifically designated as con-
5
6
3-methoxy-n-methylmorphinan and its salts (dextromethorphan). It does in-
7
clude its racemic and levorotatory forms.
8
(x) "Opium poppy" means the plant of the species Papaver somniferum L.,
9
except its seeds.
10
(y) "Peace officer" means any duly appointed officer or agent of a law
11
enforcement agency, as defined herein, including but not limited to a duly
12
13
employee of the board of pharmacy who is authorized by the board to enforce
14
15
16
(z) "Person" means individual, corporation, government, or governmen-
17
tal subdivision or agency, business trust, estate, trust, partnership or as-
18
sociation, or any other legal entity.
19
(aa) "Poppy straw" means all parts, except the seeds, of the opium poppy
20
after mowing.
21
(bb) "Practitioner" means:
22
(1) A physician, dentist, veterinarian, scientific investigator,
23
or other person licensed, registered or otherwise permitted to dis-
24
tribute, dispense, conduct research with respect to, or administer a
25
controlled substance in the course of his professional practice or re-
26
search in this state;
27
(2) A pharmacy, hospital, or other institution licensed, registered,
28
or otherwise permitted to distribute, dispense, conduct research with
29
respect to, or administer a controlled substance in the course of its
30
professional practice or research in this state.
31
(cc) "Prescribe" means a direction or authorization permitting an ulti-
32
mate user to lawfully obtain or be administered controlled substances.
33
(dd) "Prescriber" means an individual currently licensed, registered
34
or otherwise authorized to prescribe and administer controlled substances
35
in the course of professional practice.
36
(ee) "Production" includes the manufacture, planting, cultivation,
37
growing, or harvesting of a controlled substance.
38
(ff) "Simulated controlled substance" means a substance that is not a
39
controlled substance, but which by appearance or representation would lead
40
a reasonable person to believe that the substance is a controlled substance.
41
Appearance includes, but is not limited to, color, shape, size, and markings
42
of the dosage unit. Representation includes, but is not limited to, repre-
43
sentations or factors of the following nature:
44
(1) Statements made by an owner or by anyone else in control of the sub-
45
stance concerning the nature of the substance, or its use or effect;
46
(2) Statements made to the recipient that the substance may be resold
47
for inordinate profit; or
48
(3) Whether the substance is packaged in a manner normally used for il-
49
licit controlled substances.
7
1
2
state, district, commonwealth, territory, insular possession thereof, and
3
4
(hh) "Ultimate user" means a person who lawfully possesses a controlled
5
substance for his own use or for the use of a member of his household or for
6
administering to an animal owned by him or by a member of his household.
7
(ii) "Utility" means any person, association, partnership or corpora-
8
tion providing telephone and/or communication services, electricity, natu-
9
ral gas or water to the public.
10
11
amended to read as follows:
12
37-2705. SCHEDULE I. (a) The controlled substances listed in this sec-
13
tion are included in schedule I.
14
(b) Any of the following opiates, including their isomers, esters,
15
ethers, salts, and salts of isomers, esters, and ethers, unless specifically
16
excepted, whenever the existence of these isomers, esters, ethers and salts
17
is possible within the specific chemical designation:
18
(1) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-pip-
19
eridinyl]-N-phenylacetamide);
20
(2) Acetylmethadol;
21
(3) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylac-
22
etamide);
23
(4) Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacry-
24
lamide;
25
(5) Allylprodine;
26
(6) Alphacetylmethadol (except levo-alphacetylmethadol also known as
27
levo-alpha-acetylmethadol, levomethadyl acetate or LAAM);
28
(7) Alphameprodine;
29
(8) Alphamethadol;
30
(9) Alpha-methylfentanyl;
31
(10) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-
32
piperidinyl]-N-phenylpropanamide);
33
(11) Benzethidine;
34
(12) Betacetylmethadol;
35
(13) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperid-
36
inyl]-N-phenylpropanamide);
37
(14) Beta-hydroxy-3-methylfentanyl (N-(1-(2-hydroxy-2-phenethyl)-3-
38
methyl-4-piperidinyl)-N-phenylpropanamide);
39
(15) Betameprodine;
40
(16) Betamethadol;
41
(17) Betaprodine;
42
(18) Clonitazene;
43
(19) Cyclopentyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcy-
44
clopentanecarboxamide);
45
(20) Cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcy-
46
clopropanecarboxamide);
47
(21) Dextromoramide;
48
(22) Diampromide;
49
(23) Diethylthiambutene;
8
1
(24) Difenoxin;
2
(25) Dimenoxadol;
3
(26) Dimepheptanol;
4
(27) Dimethylthiambutene;
5
(28) Dioxaphetyl butyrate;
6
(29) Dipipanone;
7
(30) Ethylmethylthiambutene;
8
(31) Etonitazene;
9
(32) Etoxeridine;
10
(33) Fentanyl-related substances. "Fentanyl-related substances"
11
means any substance not otherwise listed and for which no exemption or
12
approval is in effect under section 505 of the federal food, drug, and
13
cosmetic act, 21 U.S.C. 355, and that is structurally related to fen-
14
tanyl by one (1) or more of the following modifications:
15
i. Replacement of the phenyl portion of the phenethyl group by any
16
monocycle, whether or not further substituted in or on the monocy-
17
cle;
18
ii. Substitution in or on the phenethyl group with alkyl, alkenyl,
19
alkoxyl, hydroxyl, halo, haloalkyl, amino, or nitro groups;
20
iii. Substitution in or on the piperidine ring with alkyl,
21
alkenyl, alkoxyl, ester, ether, hydroxyl, halo, haloalkyl, amino,
22
or nitro groups;
23
iv. Replacement of the aniline ring with any aromatic monocycle,
24
whether or not further substituted in or on the aromatic monocy-
25
cle; and/or
26
v. Replacement of the N-propionyl group by another acyl group;
27
(34)
4-Fluoroisobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-
28
phenethylpiperidin-4-yl)isobutyramide);
29
(35) Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-
30
2-carboxamide);
31
(36) Furethidine;
32
(37) Hydroxypethidine;
33
(38) Isobutyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-
34
phenylisobutyramide);
35
(39) Ketobemidone;
36
(40) Levomoramide;
37
(41) Levophenacylmorphan;
38
(42) 3-Methylfentanyl;
39
(43) 3-methylthiofentanyl (N-[(3-methyl-1-(2-thienyl)ethyl-4-pip-
40
eridinyl]-N-phenylpropanamide);
41
(44) Morpheridine;
42
(45) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
43
(46) MT-45 (1-cyclohexyl-4- (1,2-diphenylethyl)piperazine);
44
(47) Noracymethadol;
45
(48) Norlevorphanol;
46
(49) Normethadone;
47
(50) Norpipanone;
48
(51) Ocfentanil (N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperi-
49
din-4-yl) acetamide);
9
1
(52) Para-chloroisobutyryl fentanyl (N-(4-chlorophenyl)-N-(1-
2
phenethylpiperidin-4-yl) isobutyramide);
3
(53) Para-fluorobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-
4
phenethylpiperidin-4-yl) butyramide);
5
(54) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-
6
piperidinyl] propanamide);
7
(55) Para-methoxybutyryl fentanyl (N-(4-methoxyphenyl)-N-(1-
8
phenethylpiperidin-4-yl) butyramide);
9
(56) PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
10
(57) Phenadoxone;
11
(58) Phenampromide;
12
(59) Phenomorphan;
13
(60) Phenoperidine;
14
(61) Piritramide;
15
(62) Proheptazine;
16
(63) Properidine;
17
(64) Propiram;
18
(65) Racemoramide;
19
(66) Tetrahydrofuranyl fentanyl (N-(1-phenethylpiperidine-4-yl)-N-
20
phenyltetrahydrofuran-2-carboxamide);
21
(67) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-
22
propanamide);
23
(68) Tilidine;
24
(69) Trimeperidine;
25
(70) u-47700 (3,4-Dichloro-N-[2-(dimethylamino)cyclohexyl]-N-
26
methylbenzamide);
27
(71) Valeryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylpen-
28
tanamide).
29
(c) Any of the following opium derivatives, their salts, isomers and
30
salts of isomers, unless specifically excepted, whenever the existence of
31
these salts, isomers and salts of isomers is possible within the specific
32
chemical designation:
33
(1) Acetorphine;
34
(2) Acetyldihydrocodeine;
35
(3) Benzylmorphine;
36
(4) Codeine methylbromide;
37
(5) Codeine-N-Oxide;
38
(6) Cyprenorphine;
39
(7) Desomorphine;
40
(8) Dihydromorphine;
41
(9) Drotebanol;
42
(10) Etorphine (except hydrochloride salt);
43
(11) Heroin;
44
(12) Hydromorphinol;
45
(13) Methyldesorphine;
46
(14) Methyldihydromorphine;
47
(15) Morphine methylbromide;
48
(16) Morphine methylsulfonate;
49
(17) Morphine-N-Oxide;
50
(18) Myrophine;
10
1
(19) Nicocodeine;
2
(20) Nicomorphine;
3
(21) Normorphine;
4
(22) Pholcodine;
5
(23) Thebacon.
6
(d) Hallucinogenic substances. Any material, compound, mixture or
7
preparation which that contains any quantity of the following hallucino-
8
genic substances, their salts, isomers and salts of isomers, unless specifi-
9
cally excepted, whenever the existence of these salts, isomers, and salts of
10
isomers is possible within the specific chemical designation (for purposes
11
of this paragraph subsection only, the term "isomer" includes the optical,
12
position and geometric isomers):
13
(1) Dimethoxyphenethylamine, or any compound not specifically
14
excepted or listed in another schedule that can be formed from
15
dimethoxyphenethylamine by replacement of one (1) or more hydrogen
16
atoms with another atom(s), functional group(s) or substructure(s)
17
including, but not limited to, compounds such as DOB, DOC, 2C-B,
18
25B-NBOMe;
19
(2) Methoxyamphetamine or any compound not specifically excepted or
20
listed in another schedule that can be formed from methoxyamphetamine
21
by replacement of one (1) or more hydrogen atoms with another atom(s),
22
functional group(s) or substructure(s) including, but not limited to,
23
compounds such as PMA and DOM;
24
(3) 5-methoxy-3,4-methylenedioxy-amphetamine;
25
(4) 5-methoxy-N,N-diisopropyltryptamine;
26
(5) Amphetamine or methamphetamine with a halogen substitution on the
27
benzyl ring, including compounds such as fluorinated amphetamine and
28
fluorinated methamphetamine;
29
(6) 3,4-methylenedioxy amphetamine;
30
(7) 3,4-methylenedioxymethamphetamine (MDMA);
31
(8) 3,4-methylenedioxy-N-ethylamphetamine (also known as N-et-
32
hyl-alpha-methyl-3,4 (methylenedioxy) phenethylamine, and N-et-
33
hyl MDA, MDE, MDEA);
34
(9) N-hydroxy-3,4-methylenedioxyamphetamine (also known as N-hyd-
35
roxy-alpha-methyl-3,4(methylenedioxy) phenethylamine, and N-hyd-
36
roxy MDA);
37
(10) 3,4,5-trimethoxy amphetamine;
38
(11) 5-methoxy-N,N-dimethyltryptamine (also known as 5-methoxy-3-2[2-
39
(dimethylamino)ethyl]indole and 5-MeO-DMT);
40
(12) Alpha-ethyltryptamine (some other names: etryptamine, 3-(2-am-
41
inobutyl) indole);
42
(13) Alpha-methyltryptamine;
43
(14) Bufotenine;
44
(15) Diethyltryptamine (DET);
45
(16) Dimethyltryptamine (DMT);
46
(17) Ibogaine;
47
(18) Lysergic acid diethylamide;
48
(19) Marihuana;
49
(20) Mescaline;
50
(21) Parahexyl;
11
1
(22) Peyote;
2
(23) N-ethyl-3-piperidyl benzilate;
3
(24) N-methyl-3-piperidyl benzilate;
4
(25) Psilocybin;
5
(26) Psilocyn;
6
(27) Tetrahydrocannabinols or synthetic equivalents of the substances
7
contained in the plant, or in the resinous extractives of Cannabis, sp.
8
and/or synthetic substances, derivatives, and their isomers with simi-
9
lar chemical structure such as the following:
10
i. Tetrahydrocannabinols, except for the permitted amount of
11
tetrahydrocannabinol found in industrial hemp, or nabiximols in a
12
13
tration:
14
a. ∆
1
cis or trans tetrahydrocannabinol, and their opti-
15
cal isomers, excluding dronabinol in sesame oil and encapsu-
16
lated in either a soft gelatin capsule or in an oral solution
17
in a drug product approved by the U.S. Food and Drug Adminis-
18
tration.
19
b. ∆
6
cis or trans tetrahydrocannabinol, and their optical
20
isomers.
21
c. ∆
3,4
cis or trans tetrahydrocannabinol, and its optical
22
isomers. (Since nomenclature of these substances is not in-
23
ternationally standardized, compounds of these structures,
24
regardless of numerical designation of atomic positions are
25
covered.)
26
d. [(6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2methy-
27
loctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-
28
1-o1)], also known as 6aR-trans-3-(1,1-dimethylhep-
29
tyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-6H-
30
dibenzo[b,d]pyran-9-methanol (HU-210) and its geometric
31
isomers (HU211 or dexanabinol).
32
ii. The following synthetic drugs:
33
a. Any compound structurally derived from (1H-indole-3-
34
yl)(cycloalkyl, cycloalkenyl, aryl)methanone, or (1H-in-
35
dole-3-yl)(cycloalkyl, cycloalkenyl, aryl)methane, or
36
(1H-indole-3-yl)(cycloalkyl, cycloalkenyl, aryl), methyl
37
or dimethyl butanoate, amino-methyl (or dimethyl)-1-oxobu-
38
tan-2-yl) carboxamide by substitution at the nitrogen atoms
39
of the indole ring or carboxamide to any extent, whether or
40
not further substituted in or on the indole ring to any ex-
41
tent, whether or not substituted to any extent in or on the
42
cycloalkyl, cycloalkenyl, aryl ring(s) (substitution in the
43
ring may include, but is not limited to, heteroatoms such as
44
nitrogen, sulfur and oxygen).
45
b. N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluo-
46
ropentyl)-1 H-indazole-3-carboxamide (5F-AB-PINACA).
47
c. 1-(1.3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one
48
(N-ethylpentylone, ephylone).
49
d. 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1 H-inda-
50
zole-3-carboxamide (4-cn-cumyl-BUTINACA).
12
1
e. Ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3carboxam-
2
ido)-3,3-dimethylbutanoate * (5f-edmbpinaca).
3
f. (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3tetram-
4
ethylcyclopropyl)methanone (fub-144).
5
g. 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-inda-
6
zole-3-carboxamide (5f-cumyl-pinaca; sgt25).
7
h. (1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1
8
H-pyrrolo[2.3-B]pyridine-3-carboxamide(5fcumyl-P7AICA).
9
i. Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxam-
10
ido)-3-methylbutanoate (MMB-CHMICA, AMB-CHMICA).
11
j. Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxam-
12
ido)-3,3-dimethylbutanoate (MDMB-CHMICA).
13
k. Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxam-
14
ido-3,3-dimethylbutanoate (MDMB-FUBINACA).
15
l. Methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxam-
16
ido)-3,3-dimethylbutanoate (5F-MDMBPICA).
17
m. Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxam-
18
ido)-3,3-dimethylbutanoate (5F-ADB, 5FMDMB-PINACA).
19
n. Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxam-
20
ido)-3-methylbutanoate (5FAMB).
21
o. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluo-
22
robenzyl)-1H-indazole-3-carboxamide (ADB-FUBINACA).
23
p. N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-
24
carboxamide (FUB-AKB48; FUB-APINACA).
25
q. N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-
26
carboxamide (5F-APINACA, 5F-AKB48).
27
r. Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-car-
28
boxylate (NM2201; CBL2201).
29
s. Any compound structurally derived from 3-(1-naph-
30
thoyl)pyrrole by substitution at the nitrogen atom of the
31
pyrrole ring to any extent, whether or not further sub-
32
stituted in the pyrrole ring to any extent, whether or not
33
substituted in the naphthyl ring to any extent.
34
t. Any compound structurally derived from 1-(1-naphthyl-
35
methyl)indene by substitution at the 3-position of the in-
36
dene ring to any extent, whether or not further substituted
37
in the indene ring to any extent, whether or not substituted
38
in the naphthyl ring to any extent.
39
u. Any compound structurally derived from 3-pheny-
40
lacetylindole by substitution at the nitrogen atom of the
41
indole ring to any extent, whether or not further substi-
42
tuted in the indole ring to any extent, whether or not sub-
43
stituted in the phenyl ring to any extent.
44
v. Any compound structurally derived from 2-(3-hydroxycy-
45
clohexyl)phenol by substitution at the 5-position of the
46
phenolic ring to any extent, whether or not substituted in
47
the cyclohexyl ring to any extent.
48
w. Any compound structurally derived from 3-(benzoyl)in-
49
dole structure with substitution at the nitrogen atom of
50
the indole ring to any extent, whether or not further sub-
13
1
stituted in the indole ring to any extent and whether or not
2
substituted in the phenyl ring to any extent.
3
x. [2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrol-
4
o[1,2,3-de]-1,4-benzoxazin-6-yl]-1-napthalenylmethanone
5
(WIN-55,212-2).
6
y. 3-dimethylheptyl-11-hydroxyhexahydrocannabinol (HU-
7
243).
8
z. [(6S, 6aR, 9R, 10aR)-9-hydroxy-6-methyl-3-[(2R)-
9
5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahy-
10
drophenanthridin-1-yl]acetate (CP 50,5561).
11
(28) Ethylamine analog of phencyclidine:N-ethyl-1-phenylcy-
12
clohexylamine (1-phenylcyclohexyl) ethylamine; N-(1-phenylcy-
13
clohexyl) ethylamine, cyclohexamine, PCE;
14
(29) Pyrrolidine analog of phencyclidine: 1-(phenylcyclohexyl) -
15
pyrrolidine, PCPy, PHP;
16
(30) Thiophene analog of phencyclidine 1-[1-(2-thienyl)-cyclohexyl]-
17
piperidine, 2-thienylanalog of phencyclidine, TPCP, TCP;
18
(31) 1-[1-(2-thienyl) cyclohexyl] pyrrolidine another name: TCPy;
19
(32) Spores or mycelium capable of producing mushrooms that contain
20
psilocybin or psilocin.
21
(e) Unless specifically excepted or unless listed in another schedule,
22
any material, compound, mixture or preparation which contains any quantity
23
of the following substances having a depressant effect on the central ner-
24
vous system, including its salts, isomers, and salts of isomers whenever the
25
existence of such salts, isomers, and salts of isomers is possible within the
26
specific chemical designation:
27
(1) Gamma hydroxybutyric acid (some other names include GHB; gam-
28
ma-hydroxybutyrate, 4-hydroxybutyrate; 4-hyroxybutanoic acid; sod-
29
ium oxybate; sodium oxybutyrate);
30
(2) Flunitrazepam (also known as "R2," "Rohypnol");
31
(3) Mecloqualone;
32
(4) Methaqualone.
33
(f) Stimulants. Unless specifically excepted or unless listed in an-
34
other schedule, any material, compound, mixture, or preparation which con-
35
tains any quantity of the following substances having a stimulant effect on
36
the central nervous system, including its salts, isomers, and salts of iso-
37
mers:
38
(1) Aminorex (some other names: aminoxaphen, 2-amino-5-phenyl-2-ox-
39
azoline, or 4,5-dihydro-5-phenyl-2-oxazolamine);
40
(2) Cathinone (some other names: 2-amino-1-phenol-1-propanone, alp-
41
ha-aminopropiophenone, 2-aminopropiophenone and norephedrone);
42
(3) Substituted cathinones. Any compound, except bupropion or com-
43
pounds listed under a different schedule, structurally derived from
44
2-aminopropan-1-one by substitution at the 1-position with either
45
phenyl, naphthyl or thiophene ring systems, whether or not the compound
46
is further modified in any of the following ways:
47
i. By substitution in the ring system to any extent with alkyl,
48
alkylenedioxy, alkoxy, haloalkyl, hydroxyl or halide sub-
49
stituents, whether or not further substituted in the ring system
50
by one (1) or more other univalent substituents;
14
1
ii. By substitution at the 3-position with an acyclic alkyl sub-
2
stituent;
3
iii. By substitution at the 2-amino nitrogen atom with alkyl,
4
dialkyl, benzyl or methoxybenzyl groups, or by inclusion of the
5
2-amino nitrogen atom in a cyclic structure.
6
(4) Alpha-pyrrolidinoheptaphenone* (PV8);
7
(5) Alpha-pyrrolidinohexanophenone* (a-php);
8
(6) 4-chloro-alpha-pyrrolidinovalerophenone* (4chloro-a-pvp);
9
(7) Fenethylline;
10
(8) Methcathinone (some other names: 2-(methyl-amino)-propioph-
11
enone, alpha-(methylamino)-propiophenone, N-methylcathinone, AL-
12
464, AL-422, AL-463 and UR1423);
13
(9) (+/-)cis-4-methylaminorex [(+/-)cis-4,5-dihydro-4-methyl-5-
14
phenyl-2-oxazolamine];
15
(10) 4-methyl-alpha-ethylaminopentiophenone* (4meap);
16
(11) 4'-methyl-alpha-pyrrolidinohexiophenone* (mphp);
17
(12) N-benzylpiperazine (also known as: BZP, 1-benzylpiperazine);
18
(13) N-ethylamphetamine;
19
(14) N-ethylhexedrone*;
20
(15) N,N-dimethylamphetamine (also known as: N,N-alpha-trimethyl-
21
benzeneethanamine).
22
SECTION 3. An emergency existing therefor, which emergency is hereby
23
declared to exist, this act shall be in full force and effect on and after
24
July 1, 2022.